Variable | Case group | Control group | P value |
---|---|---|---|
Median age (y) | 49 | 48 | ND |
Age range (y) | 27–72 | 28–70 | ND |
Male | 56 (88.9) | 56 (88.9) | ND |
Female | 7 (11.1) | 7 (11.1) | ND |
N-classification | 0.069 | ||
 N0–1 | 31 (49.2) | 41 (65.1) | |
 N2–3 | 32 (50.8) | 22 (34.9) | |
AJCC 2010 stage | 0.752 | ||
 IVA | 58 (92.1) | 57 (90.5) | |
 IVB | 5 (7.9) | 6 (9.5) | |
Chemotherapy | |||
 Induction | 60 (95.2) | 56 (88.9) | 0.187 |
 Concurrent | 36 (57.1) | 42 (66.7) | 0.271 |
 Adjuvant | 20 (31.7) | 19 (30.2) | 1.000 |
Concurrent cetuximab or nimotuzumab | 7 (11.1) | 3 (4.8) | 0.187 |
Nasopharynx boost | 4 (6.3) | 1 (1.6) | 0.365a |
Overall treatment time (OTT) | 0.859 | ||
 ≤ 45 | 25 (39.7) | 19 (30.1) | |
 > 45 | 38 (60.3) | 44 (69.8) | |
Temporal lobe Dmax (Gy) | 75.22 (63.83–80.16) | 72.64 (61.35–79.35) | < 0.001 |
Temporal lobe D1cc (Gy) | 72.52 (54.47–77.21) | 66.81 (54.40–74.95) | < 0.001 |
Temporal lobe V20 (cc) | 48.18 (21.26–75.20) | 38.06 (15.01–79.18) | < 0.001 |
Temporal lobe V30 (cc) | 31.64 (10.22–56.35) | 23.94 (8.55–55.09) | < 0.001 |
Temporal lobe V40 (cc) | 20.11 (6.09–43.16) | 15.09 (5.63–37.47) | < 0.001 |
Temporal lobe V50 (cc) | 13.23 (2.76–31.28) | 8.84 (2.23–29.56) | < 0.001 |
Temporal lobe V60 (cc) | 7.59 (0.2–19.71) | 3.65 (0.24–19.45) | < 0.001 |
Temporal lobe V70 (cc) | 2, 26 (0–9.18) | 0.26 (0–8.22) | < 0.001 |